A systematic review of immediate anticoagulation for ischemic stroke of presumed cardioembolic origin

Stroke

Volumn 39, Issue 5, 2008, Pages

  Guedes, Leonor C ^a   Ferro, José M ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EMBOLISM; HUMAN; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; TREATMENT OUTCOME; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; HEART DISEASE; META ANALYSIS; NOTE; PATHOPHYSIOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK ASSESSMENT; STANDARD;

ANTICOAGULANTS; BRAIN ISCHEMIA; HEART DISEASES; HUMANS; INTRACRANIAL EMBOLISM; INTRACRANIAL HEMORRHAGES; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 44449084993     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.513200     Document Type: Letter

References (9)

1. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423-430.
2. Correia Guedes L, Ferro JM. Immediate anticoagulation of ischaemic stroke of presumed cardioembolic origin. J Neurol. 2006; 253 (Suppl 2): II112.
3. Cerebral Embolism Study Group (CESG). Immediate anticoagulation of embolic stroke: a randomized trial. Stroke. 1983;14:668-676.
4. International Stroke Trial Collaborative (IST) Group. The IST. A randomized trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischemic stroke. Lancet. 1997;349: 1569-1581.
5. Hommel M for the FISS-bis Investigators Group. Fraxiparine in Ischemic Stroke Study (FISS bis) [Abstract]. Cerebrovasc Dis. 1998;8(suppl):19.
6. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA. 1998;279:1265-1272.
7. Berge E, Abdelnoor M, Nakstad PH, Sandset PM, HAEST Study Group. Low molecular-weight heparin versus aspirin in patients with acute is-chemic stroke and atrial fibrillation. A double-blind randomised study. Lancet. 2000;355:1205-1210.
8. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in acute ischemic stroke (TAIST): a randomized aspirin-controlled trial. Lancet. 2001;358:702-710.
9. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36:2415-2420.